ArticleEuropean urology2024
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
Article in European urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.Annals of surgical oncology · 2026Review
- No racial disparities in prostate cancer-specific mortality after biochemical recurrence following radical prostatectomy or radiation therapy.Prostate cancer and prostatic diseases · 2026Article
- Baseline Ga-68 PSMA PET/CT-derived volumetric parameters as predictors of biochemical recurrence following radical prostatectomy.Annals of nuclear medicine · 2026Article
- Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer - a multicentre evaluation.European journal of nuclear medicine and molecular imaging · 2026Article
- Biochemical recurrence following definitive treatment of prostate cancer in Brazil: a retrospective cohort study.BMC urology · 2026Observational
- Article
- Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy.BJU international · 2026Article
- Ensemble Optimal Control for Managing Drug Resistance in Cancer Therapies.Bulletin of mathematical biology · 2026Article
- Cancer-specific mortality differences between radical prostatectomy and radiotherapy after biochemical recurrence: analysis of a health system-wide cohort.World journal of urology · 2026Article
- Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy.European journal of nuclear medicine and molecular imaging · 2026Article
- Postprostatectomy prostate cancer treated with radiation therapy: adverse features and androgen deprivation therapy use in a statewide consortium.JNCI cancer spectrum · 2025Article
- A comparative analysis of robotic prostatectomy techniques post TURP/HOLEP: retzius-sparing vs. non-retzius approaches: evaluation of perioperative, functional, and oncological outcomes.International urology and nephrology · 2025Article
- Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse.Abdominal radiology (New York) · 2025Review
- DWI-based Biologically Interpretable Radiomic Nomogram for Predicting 1-year Biochemical Recurrence after Radical Prostatectomy: A Deep Learning, Multicenter Study.Current medical imaging · 2025Article
- The Prognostic Value of Perioperative Factors on Biochemical Recurrence in Patients Undergoing Radical Prostatectomy.Research and reports in urology · 2025Article
- Advances in research regarding epithelial-mesenchymal transition and prostate cancer.Frontiers in cell and developmental biology · 2025Review
- Secondary Analysis of PSA and BCR-Free Survival in Asian Prostate Cancer Patients.Cancer management and research · 2025Article
- Radiation Therapy for Local or Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.Research and reports in urology · 2025Article
- How to tailor the radiotherapy after radical prostatectomy in the modern era of molecular imaging, genomic testing, and technology development?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Review
- Helpful tool or blunt instrument?-the European Association of Urology Biochemical Recurrence Risk Classification as a decision-making tool for salvage radiotherapy.Translational andrology and urology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
20 authors at 15 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe European Association of Urology (EAU) has proposed a risk stratification for patients harboring biochemical recurrence (BCR) after radical prostatectomy (RP).
objectiveTo assess whether this risk stratification helps in choosing patients for salvage radiotherapy (SRT). DESIGN, SETTING, AND
participantsAnalyses of 2379 patients who developed BCR after RP (1989-2020), within ten European high-volume centers, were conducted. Early and late SRT were defined as SRT delivered at prostate-specific antigen values <0.5 and ≥0.5 ng/ml, respectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox models tested the effect of SRT versus no SRT on death and cancer-specific death. The Simon-Makuch method tested for survival differences within each risk group. RESULTS AND LIMITATIONS: Overall, 805 and 1574 patients were classified as having EAU low- and high-risk BCR. The median follow-up was 54 mo after BCR for survivors. For low-risk BCR, 12-yr overall survival was 87% versus 78% (p = 0.2) and cancer-specific survival was 100% versus 96% (p = 0.2) for early versus no SRT. For high-risk BCR, 12-yr overall survival was 81% versus 66% (p < 0.001) and cancer-specific survival was 98% versus 82% (p < 0.001) for early versus no SRT. In multivariable analyses, early SRT decreased the risk for death (hazard ratio [HR]: 0.55, p < 0.01) and cancer-specific death (HR: 0.08, p < 0.001). Late SRT was a predictor of cancer-specific death (HR: 0.17, p < 0.01) but not death (p = 0.1).
conclusionsImproved survival was recorded within the high-risk BCR group for patients treated with early SRT compared with those under observation. Our results suggest recommending early SRT for high-risk BCR men. Conversely, surveillance might be suitable for low-risk BCR, since only nine patients with low-risk BCR died from prostate cancer during follow-up. PATIENT SUMMARY: The impact of salvage radiotherapy (SRT) on cancer-specific outcomes stratified according to the European Association of Urology biochemical recurrence (BCR) risk classification was assessed. While men with high-risk BCR should be offered SRT, surveillance might be a suitable option for those with low-risk BCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.